4th Quarter - Report — COLLIER COLLECTIVE, LLC for DRUG POLICY ACTION (2022)

Firm

COLLIER COLLECTIVE, LLC

Client

DRUG POLICY ACTION

Income

$40,000

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

1. Advocated for increased FY23 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.

Lobbyist	Covered position, as disclosed
JENNY COLLIER	—
DANIELLE NEAL	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Office of Natl Drug Control Policy (NDCP)

Law Enforcement/Crime/Criminal Justice LAW

Advocated on the effectiveness of overdose prevention centers and the need for the Administration to permit and support this intervention in the U.S. to help save lives by reducing drug overdose deaths.

Lobbyist	Covered position, as disclosed
JENNY COLLIER	—

Contacted: Office of Natl Drug Control Policy (NDCP); Justice, Dept of (DOJ)

Health Issues HCR

Advocated for not including or limiting the ban on the use of federal funds to purchase safe supplies for the use of drugs to reduce the transmission of infectious diseases and reduce drug overdoses in H.R. HR 7666, "The Restoring Hope for Mental Health and Well-Being Act of 2022."

Lobbyist	Covered position, as disclosed
JENNY COLLIER	—

Contacted: HOUSE OF REPRESENTATIVES; Office of Natl Drug Control Policy (NDCP); SENATE

Bills named: H.R. 7666 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.